Ads
related to: colace classification and action potential chart for diabetes 1 and 4- See the FAQs
Get the Answers to Frequently
Asked Questions Today.
- View Patient Stories
Watch Videos of Patient Stories
Today to Start Your T1D Journey.
- Join the Support Program
View Resources & Copay Assistance.
Terms & Conditions Apply.
- Talk to Your Doctor
Download the Discussion Guide
to Start the Conversation Today.
- View T1D Organizations
Stay Connected. Learn About
T1D Organizations Today.
- Get Screened Today
Discover the Importance of Early
Screening. Learn More Now.
- See the FAQs
Search results
Results From The WOW.Com Content Network
Docusate is the common chemical and pharmaceutical name of the anion bis(2-ethylhexyl) sulfosuccinate, also commonly called dioctyl sulfosuccinate (DOSS). [2] [3] [4]Salts of this anion, especially docusate sodium, are widely used in medicine as an emollient laxative and as stool softeners, by mouth or rectally. [1]
This category reflects the organization of Anatomical Therapeutic Chemical Classification System code A10. Generally, drugs outlined within the ATC code A10 should be included in this category. Please see WP:PHARM:CAT for more information.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup A10 is part of the anatomical group A Alimentary tract and ...
In patients with diabetes mellitus type 1, alpha-glucosidase inhibitors use has not been officially approved by the Food and Drug Administration in the US but some data exists on the effectiveness in this population, showing potential benefits weighted against an increased risk of hypoglycemia. [18]
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
The annual cost of insulin for people with type 1 diabetes in the US almost doubled from $2,900 to $5,700 over the period from 2012 to 2016. [97] In 2019, it was estimated that people in the US pay two to six times more than the rest of the world for brand name prescription medicine, according to the International Federation of Health Plans. [98]
Ad
related to: colace classification and action potential chart for diabetes 1 and 4